With the anti-CTLA-4 and the anti-PD-1 treatment, all the “responsive” and “partially responsive” models demonstrated statistical decrease in the percentage of Ki67+ glioma cells in comparison with corresponding untreated controls (Figure 5). Here, MKI67 is linked to central nervous system cancer.